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Neurosyphilis Increases Human Immunodeficiency Virus 
(HIV)-associated Central Nervous System Inflammation 
but Does Not Explain Cognitive Impairment in HIV-
infected Individuals With Syphilis
Emily L. Ho,1 Clare L. Maxwell,2 Shelia B. Dunaway,3 Sharon K. Sahi,2 Lauren C. Tantalo,2 Sheila A. Lukehart,3,4 and Christina M. Marra2
1Department of Neurology, Swedish Neuroscience Institute, Seattle, and Departments of 2Neurology, 3Medicine, and 4Global Health, University of Washington, Seattle
Background. Individuals infected with human immunodeficiency virus (HIV) who have previously had syphilis may have cog-
nitive impairment. We tested the hypothesis that neurosyphilis causes cognitive impairment in HIV by amplifying HIV-related 
central nervous system (CNS) inflammation.
Methods. One hundred thirty-two HIV-infected participants enrolled in a study of cerebrospinal fluid (CSF) abnormalities 
in syphilis underwent the mental alternation test (MAT), venipuncture, and lumbar puncture. CSF concentrations of chemokine 
(C-X-C motif) ligand 10 (CXCL10), chemokine (C-C motif) ligand 2 (CCL2), and neurofilament light (NFL) were determined by 
commercial assays. The proportion of peripheral blood mononuclear cells (PBMCs) and of CSF white blood cells (WBCs) that were 
activated monocytes (CD14+CD16+) was determined by flow cytometry. Neurosyphilis was defined as detection of Treponema pal-
lidum 16S RNA in CSF or CSF white blood cells (WBCs) >20/uL or a reactive CSF-Venereal Disease Research Laboratory (VDRL) 
test; uncomplicated syphilis was defined as undetectable CSF T. pallidum, CSF WBCs ≤5/uL and nonreactive CSF-VDRL. MAT <18 
was considered low.
Results. Median proportion of PBMCs that were activated monocytes (16.6 vs. 5.3), and median CSF CXCL10 (10 658 vs. 2530 
units), CCL2 (519 vs. 337 units) and HIV RNA (727 vs. 50 c/mL) were higher in neurosyphilis than in uncomplicated syphilis (P ≤ 
.001 for all comparisons). Neurosyphilis was not related to low MAT scores. Participants with low MAT scores had higher median 
CSF CXCL10 (10 299 vs. 3650 units, P = .008) and CCL2 (519 vs. 365 units, P = .04) concentrations than those with high MAT scores.
Conclusions. Neurosyphilis may augment HIV-associated CNS inflammation, but it does not explain cognitive impairment in 
HIV-infected individuals with syphilis.
Keywords. HIV; syphilis; neurosyphilis; cognitive impairment; inflammation.
 
The rate of primary and secondary syphilis in the United States 
has progressively increased since 2001, with a 19% increase 
between 2014 and 2015 [1]. In 2015, most cases were in men 
who have sex with men, and 50% of them were infected with 
human immunodeficiency virus (HIV) [1]. Treponema pal-
lidum subsp pallidum (hereafter T. pallidum) is highly neuroin-
vasive. Neuroinvasion, defined by identifying living organisms 
or their nucleic acid in cerebrospinal fluid (CSF), may be seen in 
as many as 40% of patients with early syphilis [2] and does not 
differ in those who are HIV-infected compared to those who are 
not [3]. However, asymptomatic or symptomatic neurosyphilis 
defined as reactive CSF-Venereal Disease Research Laboratory 
(VDRL), CSF pleocytosis, or both, without or with neurologi-
cal abnormalities, may be more common in HIV-infected com-
pared to HIV-uninfected individuals with syphilis [4].
We previously showed that HIV-infected individuals with a 
prior episode of syphilis had neurocognitive impairment com-
pared to appropriate HIV-infected controls [5]. Similar findings 
have been reported by others [6, 7], even among individuals with 
acute HIV infection [8]. Six of 100 individuals in our study had 
a reactive CSF-VDRL, and they had significantly higher CSF 
white blood cell (WBC) and CSF HIV RNA concentrations than 
those with a nonreactive CSF-VDRL. There was no significant 
relationship between reactive CSF-VDRL and neuropsycholog-
ical test performance, but the number of individuals with reac-
tive CSF-VDRL was small [5]. Among HIV-infected individuals 
with detectable plasma HIV RNA, an earlier retrospective study 
showed that CSF WBC and CSF HIV RNA were significantly 
higher in those with past neurosyphilis than in those with pre-
vious uncomplicated syphilis or no history of syphilis [9]. No 
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neuropsychological testing was performed. The authors sug-
gested that immune activation due to neurosyphilis could 
amplify central nervous system (CNS) HIV infection and pre-
dispose affected individuals to future cognitive impairment [9].
Cognitive impairment is common in HIV-infected individ-
uals, even in the setting of control of peripheral viremia [10]. 
Its pathogenesis remains incompletely understood, but ongoing 
inflammation in the CNS compartment may play a role [11]. 
We hypothesized that neurosyphilis causes cognitive impair-
ment in HIV-infected individuals, and that greater cognitive 
impairment in HIV-infected individuals with a history of syph-
ilis is due to amplification of HIV-related CNS inflammation 
by neurosyphilis. We aimed to test this hypothesis in a cohort 
of HIV-infected patients with uncomplicated syphilis and 
neurosyphilis.
METHODS
Characteristics of Study Participants
Participants were enrolled in a study of CSF abnormalities in 
syphilis conducted in Seattle, Washington [12]. Study eligi-
bility included clinical or serological evidence of syphilis, and 
assessment by the referring provider that the patient was at risk 
for neurosyphilis. Reasons for referral to the study included 
but were not restricted to (1) neurological symptoms or signs, 
(2) serum rapid plasma reagin (RPR) titer ≥ 1:32, and (3) in 
HIV-infected individuals, peripheral blood CD4+ T-cell count 
≤ 350/mL. The 2 latter criteria increase risk of neurosyphi-
lis [12–14]. Participants underwent a structured history and 
examination that included the Mental Alternation Test (MAT, 
an oral version of the Trails B test) [15], venipuncture, and lum-
bar puncture. The study protocol was reviewed and approved by 
the University of Washington Institutional Review Board, and 
human experimentation guidelines were followed in the con-




Plasma and cell-free CSF HIV RNA, CSF-VDRL tests, and 
enumeration of CSF red blood cells (RBCs) and WBCs were 
performed in a Clinical Laboratory Improvement Amendments 
(CLIA)-approved hospital clinical laboratory. Serum RPR tests 
were performed in a research laboratory using published meth-
ods [16]. Identification of T. pallidum 16S ribosomal RNA (16S 
RNA) in CSF was performed using reverse transcriptase poly-
merase chain reaction (RT-PCR) as previously described [12].
Measurement of Cerebrospinal Fluid Chemokines and Neurofilament Light
Cell-free CSF concentrations of chemokine (C-X-C motif) 
ligand 10 (CXCL10; also known as interferon-gamma inducible 
protein 10 [IP-10]) and chemokine (C-C motif) ligand 2 (CCL2; 
also known as monocyte chemoattractant protein [MCP]-1) 
were determined by Meso Scale Discovery multiplex system 
(Meso Scale Diagnostics, Rockville, Maryland). Cell-free CSF 
concentrations of neurofilament light (NFL) were determined 
by NF-light ELISA (UmanDiagnostics AB, Umea, Sweden) 
according to the manufacturer’s instructions.
Peripheral Blood Mononuclear Cells and Cerebrospinal Fluid Preparation
Paired peripheral blood mononuclear cells (PBMCs) and 
CSF WBCs were collected from individual study participants. 
PBMCs were purified from blood collected in EDTA tubes using 
Ficoll-Paque PLUS density gradient media (Sigma-Aldrich, 
St. Louis, Missouri) according to manufacturer’s instructions. 
CSF cells were collected by centrifugation of 5–8 mL of CSF at 
200 g for 10 min. Both were preserved in a solution of 90% fetal 
bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO) in 
liquid nitrogen until use.
Flow Cytometry
CD45+ mononuclear cells were gated to define mono-
cytes (CD3-CD4+). Activated monocytes were gated for a 
CD14+CD16+ population. Antibodies included anti-CD45 
conjugated with VioBlue; anti-CD16 conjugated with PECy5; 
anti-CD14 conjugated with ECD (Beckman Coulter, Brea, 
California); anti-CD8 conjugated with QDot605; anti-CD4 
conjugated with PE; anti-CD3 conjugated with AmCyan. All 
antibodies were purchased from BD Biosciences, San Jose, 
California, except where specifically noted. Unstained PBMCs 
and CSF cells, as well as unstained and single stained BDTM 
CompBeads (BD Biosciences, San Jose, California) controls 
were prepared for optimizing fluorescence compensation set-
tings for flow cytometric analyses. Fluorescent minus one 
(FMO) controls were prepared on PBMC samples by omitting 
1 antibody and were used to evaluate fluorescence spill-over 
and assist with setting gates. Stained samples were acquired on 
a customized LSRII flow cytometer (BD Biosciences, San Jose, 
California) within 2 hours of staining. For PBMC samples, 
100 000 events were acquired; for CSF samples, the entire cell 
suspension was acquired. Analysis and compensation of data 
was performed using FlowJo (Treestar, Ashland, Oregon).
Statistical Methods
Neurosyphilis was defined as detection of T. pallidum 16S 
RNA in CSF or CSF WBCs >20/uL or a reactive CSF-VDRL. 
Uncomplicated syphilis was defined as undetectable T. pal-
lidum 16S RNA in CSF and CSF WBCs ≤5/uL and nonreactive 
CSF-VDRL. A cut-off of 18, the cut-off of the lower quartile of 
values in our participants, was used to define abnormal perfor-
mance on the MAT. Peripheral blood CD4+ T cells and plasma 
HIV RNA concentration were obtained from medical records 
and were included in analyses if they were determined within 
90 days of the study visit. Plasma and CSF HIV RNA concen-
trations ≤50 copies/mL were assigned a value of 50 copies/mL. 
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Descriptive statistics are reported as number (n) (%) or median 
(interquartile range [IQR]). Associations between categorical 
variables were assessed by χ2 or Fisher exact tests; associations 
between continuous and categorical variables were determined 
by the Mann-Whitney U test; and associations between contin-
uous variables were assessed using the Spearman rank correla-
tion coefficient. Multivariate associations were assessed using 
logistic regression. SPSS version 19 was used for all analyses. All 
tests were 2-tailed. P values < .05 were considered statistically 
significant.
RESULTS
The characteristics of the 132 HIV-infected study participants 
are shown in Table 1. Sixty-eight individuals met our definition 
of neurosyphilis: 52 had CSF WBC >20/uL, and this was the 
only CSF abnormality in 18; 28 had detection of T. pallidum 16S 
RNA in CSF, and this was the only CSF abnormality in 6; and 
36 had a reactive CSF-VDRL, and this was the only CSF abnor-
mality in 8. Consistent with other studies, individuals with neu-
rosyphilis had higher serum RPR titers, were less likely to be 
taking antiretroviral agents, and had higher plasma HIV RNA 
concentrations than those with uncomplicated syphilis [12–14, 
17, 18]. Contrary to our hypothesis, there was no difference in 
the proportion with an abnormal score (<18) on the MAT in the 
2 groups (17 [25.0%] of 68 vs. 13 [21.0%] of 62, P = .59; Table 1).
Forty-two individuals were treated for uncomplicated syphilis 
before LP. There was no significant difference in the proportion 
with an abnormal MAT score between those who were not and 
those who were treated for uncomplicated syphilis before LP (20 
[22.7%] of 88 vs. 10 [23.8%] of 42, P = .89). Similarly, there was 
no difference in the proportion with an abnormal MAT score 
between those without and with a prior episode of syphilis (27 
[25.2%] of 107 vs. 3 [13.0%] of 23, P = .21) or among those not 
currently on antiretrovirals compared to those currently on 
antiretrovirals (13 [25.5%] of 51 vs. 15 (22.4%) of 67 P = .70).
The proportion of PBMCs that were activated monocytes 
(CD14+CD16+) was significantly higher in those with neu-
rosyphilis compared to those with uncomplicated syphilis 
(Figure  1). CSF concentrations of CXCL10, CCL2, and HIV 
RNA were also significantly higher in those with neurosyphi-
lis (Figure 1), but the proportion of CSF WBCs that were acti-
vated monocytes and the CSF concentration of NFL did not 
differ between the 2 groups. Because CSF NFL concentration 
increases with age [19], the latter analysis was repeated taking 
into account participant age, and the results were unchanged. 
Results were unchanged when we restricted the analysis to indi-
viduals with plasma HIV RNA ≤ 50 copies/mL, except that CSF 
NFL concentration was significantly higher in those with neu-
rosyphilis (data not shown). The number of samples tested was 
too small to allow us to take age into account.
Among all study participants, CSF concentrations of CXCL10, 
CCL2, and HIV RNA were significantly higher in samples with 
higher CSF WBC concentrations (Table 2). We were not able to 
test for association between CXCL10 or CCL2 and neurosyphi-
lis taking into account WBC concentration because of our sam-
ple size and collinearity. Taking into account CSF WBCs, CSF 
concentration of HIV RNA did not remain significantly higher 
in individuals with neurosyphilis.
Among all study participants, those with scores <18 had higher 
CSF CXCL10 and CCL2 concentrations, lower peripheral blood 
CD4+ T cells (Figure 2) and were more likely to have a previous 
AIDS diagnosis (17 [56.7%] of 30 vs. 35 [35.4%] of 99, P = .04) 
than those with MAT scores ≥18. Low scores on the MAT were 
not significantly related to CSF concentrations of WBC, HIV 
RNA, or NFL (even taking into account age); or to age, plasma 
HIV RNA concentration or use of antiretroviral medications.
DISCUSSION
The goal of this study was to test the hypothesis that neurosyph-
ilis causes cognitive impairment in HIV-infected individuals, 
Table 1. Characteristics of the 132 Human Immunodeficiency Virus-infected Study Participants
Characteristic Uncomplicated Syphilis, n = 64 Neurosyphilis, n = 68 P-value
Male 63 (98.4) 68 (100.0) NS
Race
 Black 11 (17.2) 9 (13.2) NS
 White 47 (73.4) 55 (80.9)
 Other 6 (9.4) 4 (5.9)
Age 37 (32–43) 41 (33–48) NS
1/serum RPR titer 64 (8–128) 128 (64–512) <.001
On antiretrovirals 41 (68.3), n = 60 27 (45.0), n = 60 .01
Peripheral blood CD4 T cells/uL within 90 days 445 (227–627), n = 56 432 (303–567), n = 63 NS
Plasma HIV RNA copies/mL within 90 days 60 (50–4582), n = 57 10 765 (50–92 938), n = 64 .006
Previous AIDS diagnosis 28 (43.8) 25 (37.3), n = 67 NS
Mental alternation test score <18 13 (21.0), n = 62 17 (25.0) NS
Results are expressed as n (%) or median (interquartile range).
Abbreviations: HIV, human immunodeficiency virus; NS, not significant; RPR, rapid plasma reagin.
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and that greater cognitive impairment in HIV-infected indi-
viduals with a history of syphilis is due to amplification of 
HIV-related CNS inflammation by neurosyphilis. We focused 
on assessment of a small panel of mediators that are associated 
with cognitive impairment and CSF inflammation in patients 
infected with HIV, including peripheral blood CD14+CD16+ 
cells and CSF concentrations of CXCL10, CCL2, and NFL.
The number of circulating peripheral blood CD14+CD16+ 
monocytes is higher in HIV-infected individuals with dementia 
than in AIDS patients without dementia [20], and perivascular 
CD14+CD16+ cells, many of which are HIV-infected, accumu-
late in brains of HIV-infected individuals with dementia [21]. 
Higher CSF concentrations of CXCL10 and CCL2 are seen in 
HIV-infected patients with cognitive impairment, even in the 
setting of modern antiretroviral therapy [22], and higher CSF 
concentrations are seen in HIV-infected individuals with evi-
dence of neuronal injury by MR spectroscopy, suggesting that 
CXCL10 and CCR2 may be neurotoxic in vivo [23]. Higher 
CSF CXCL10 concentrations are seen in HIV-infected indi-
viduals with higher CSF WBC and CSF HIV RNA concentra-
tions. This finding suggests that CXCL10 contributes to CSF 
pleocytosis and amplifies local HIV infection [24]. Moreover, 
CCL2 may promote ingress of CD16+ cells into the CNS [25]. 
The CSF concentration of NFL is elevated in untreated HIV-
infected patients with dementia [26]; the association with cog-
nitive impairment is attenuated in those with controlled plasma 
viremia [19].
Our results are in accord with our hypothesis that neurosyph-
ilis augments HIV-associated CNS inflammation. In patients 
with neurosyphilis, the proportion of peripheral blood mono-
cytes that were CD14+CD16+ was significantly higher than in 
those with uncomplicated syphilis, and patients with higher 
proportion of peripheral blood CD14+CD16+ monocytes had 
higher CSF WBC concentrations. The finding that the propor-
tion of CSF WBCs that were CD14+CD16+ monocytes did not 
differ between the groups does not weaken our conclusion, 
as these cells likely migrate to perivascular locations and thus 
would not necessarily be reflected in the CSF cellular profile.
In addition to the above, CSF concentrations of HIV RNA, 
CXCL10, and CCL2 were significantly higher in those with neu-
rosyphilis compared to individuals with uncomplicated syphilis. 
Higher CSF concentrations of CXCL10 and CCL2 were seen in 
individuals with higher CSF WBC concentrations. CNS infec-
tion by T. pallidum causes CSF pleocytosis, and CSF pleocytosis 
Table 2. Correlationsa Between Cerebrospinal Fluid; and Blood Measures 
in All Study Participants







NFL NS NS NS
CSF HIV RNA .497c .585c .403b NS
CSF CD14+CD16+ NS NS NS NS NS
BLOOD 
CD14+CD16+
.521b NS NS NS NS NS
Abbreviations: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; NFL, neurofil-




Figure 1. Concentrations of CSF and peripheral blood measures in patients with uncomplicated syphilis (no NS) and neurosyphilis (NS). CXCL10 and CCL2 concentrations 
are in arbitrary units. Abbreviation: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus.
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could be the source of increased CSF concentrations of HIV 
RNA or chemokines. CXCL10 stimulates HIV replication, and 
it is neurotoxic in vitro [27]. Induction of CSF CXCL10 by neu-
rosyphilis thus has biologic plausibility for augmenting CNS 
HIV-related inflammation. Our finding that CSF CXCL10 and 
CCL2 concentrations remained higher in individuals with neu-
rosyphilis when the analysis was restricted to those with plasma 
HIV RNA ≤50 copies/mL supports the contention that higher 
CSF chemokine concentrations were due to neurosyphilis and 
not to HIV infection.
A recent study in HIV-uninfected patients with uncompli-
cated syphilis and neurosyphilis also documented elevated CSF 
CXCL10 concentrations in patients with neurosyphilis but did 
not demonstrate an association between CSF WBC and CSF 
CXCL10 concentrations [28], suggesting that CSF pleocytosis 
in our patients could reflect both T. pallidum and HIV infection. 
Moreover, that study did not identify an increase in CSF CCL2 
concentration in HIV-uninfected patients with neurosyphilis 
compared to uncomplicated syphilis as we did, suggesting that 
upregulation of CSF CCL2 in neurosyphilis may be unique to 
HIV-infected patients.
However, we were not able to support our hypothesis that 
neurosyphilis causes cognitive impairment in HIV-infected 
individuals. We did not identify a relationship between neu-
rosyphilis and abnormal cognition. However, among all study 
participants, CSF concentrations of CXCL10 and CCL2 were 
significantly higher in those with MAT scores <18 compared 
to those with scores of ≥18. These findings further support the 
contention that CXCL10 and CCL2 are neurotoxic and raise 
the question of whether simply having uncomplicated syphilis 
is sufficient to adversely impact cognition. Because we did not 
have a control group of HIV-infected individuals without syph-
ilis, we cannot address this issue.
Additional limitations of our study should be acknowledged. 
Study participants included in this analysis were chosen as an 
unmatched convenience sample. We were not able to deter-
mine the concentration of all measures in all study participants, 
which limits the power of some of our analyses. Because CSF 
CXCL10 and CCL2 were measured by Meso Scale technology, 
which provides concentrations in arbitrary units, we cannot 
compare our CSF values to published literature. We used the 
MAT as our single formal assessment of cognition [15], and we 
did not employ a comprehensive neuropsychological test bat-
tery that might have been more sensitive in detecting cognitive 
impairment. However, imprecision in our cognitive assessment 
would have weakened, rather than strengthened the associa-
tions that we identified. We used a cut-off of 18 for abnormal 
cognition, defined by the lower quartile among our partici-
pants, rather than a cut-off of 15 that was established for a diag-
nosis of dementia [15]. Our reasoning was that the cut-off of 15 
was established in a cohort of largely hospitalized HIV-infected 
patients, many of whom had AIDS, who were studied before 
the advent of combination antiretroviral therapy [15]. Thus, 
the applicability of that cut-off to our participant population is 
limited, and we opted to rely on an internal standard. We also 
wanted to identify cognitive impairment, not just frank demen-
tia. Our finding that low MAT scores were more common 
among study participants with lower peripheral blood CD4+ 
T cells and among those with a prior AIDS diagnosis supports 
the validity of our use of the MAT, as similar associations have 
Figure 2. Concentrations of CSF and peripheral blood measures in all patients 
dichotomized by MAT scores at or above 18 (≥18) vs. below 18 (<18), which is 
the score defining the lowest quartile for the study population. CXCL10 and CCL2 
concentrations are in arbitrary units. Abbreviations: CSF, cerebrospinal fluid; MAT, 
mental alternation test.
948 • CID 2017:65 (15 September) • Ho et al
been seen in HIV-infected individuals tested with more com-
prehensive neuropsychological batteries [10, 29]. Finally, we 
explored whether neurosyphilis amplifies HIV-related CNS 
inflammation, rather than the opposite, or whether the effects 
might be additive. Our findings support our supposition but do 
not exclude other possibilities. Our results should thus be con-
sidered as hypothesis generating.
Our study leaves unanswered the question of whether 
uncomplicated syphilis contributes to cognitive impairment in 
HIV-infected individuals. There is a precedent for the ability of 
peripheral processes to affect cognition. For example, a study of 
community dwelling individuals with Alzheimer disease showed 
that those who experienced an acute systemic inflammatory 
event such as urinary tract infection, myocardial infarction, or 
accidental trauma had a higher rate of cognitive decline over the 
ensuing 6  months compared to those without acute systemic 
inflammatory events [30]. Additionally, among HIV-infected 
individuals, chronic infections, for example, hepatitis C virus or 
even seropositivity for toxoplasmosis without evidence of CNS 
disease, may adversely affect cognition [31, 32]. Future study of 
HIV-infected individuals with and without syphilis and neu-
rosyphilis is required to better understand the etiology of cogni-
tive impairment in HIV-infected individuals with syphilis.
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